Cancer pharmacogenetics: polymorphisms, pathways and beyond
- 1 December 2003
- journal article
- review article
- Published by Springer Nature in Nature Reviews Cancer
- Vol. 3 (12), 912-920
- https://doi.org/10.1038/nrc1233
Abstract
No abstract availableKeywords
This publication has 58 references indexed in Scilit:
- Pharmacogenetics affects dosing, efficacy, and toxicity of cytochrome P450–metabolized drugsAmerican Journal Of Medicine, 2002
- Implications of Dihydropyrimidine Dehydrogenase on 5-Fluorouracil Pharmacogenetics and PharmacogenomicsPharmacogenomics, 2002
- Pharmacogenetics and Folate Metabolism –a Promising DirectionPharmacogenomics, 2002
- The thiopurine S-methyltransferase gene locus – implications for clinical pharmacogenomicsPharmacogenomics, 2002
- Pharmacogenetics and cancer therapyNature Reviews Cancer, 2001
- Preponderance of Thiopurine S-Methyltransferase Deficiency and Heterozygosity Among Patients Intolerant to Mercaptopurine or AzathioprineJournal of Clinical Oncology, 2001
- Can dihydropyrimidine dehydrogenase impact 5-fluorouracil-based treatment?European Journal Of Cancer, 2000
- Mercaptopurine Therapy Intolerance and Heterozygosity at the Thiopurine S-Methyltransferase Gene LocusJNCI Journal of the National Cancer Institute, 1999
- Phenotype-genotype correlation of in vitro SN-38 (active metabolite of irinotecan) and bilirubin glucuronidation in human liver tissue with UGT1A1 promoter polymorphismClinical Pharmacology & Therapeutics, 1999
- The pharmacogenetics of codeine hypoalgesiaPharmacogenetics, 1995